Menu Close

Trending

Roche, Boehringer tap biosensor firms for patient studies
A new dawn of the genomic age: five areas set to be transformed in 2023
ABPI code updated with first social media guidance
NICE recommends first CAR-T cell therapy on NHS in England
EU clears Enhertu for HER2-low breast cancer

pharma news

Keytruda-840x480

News/ News/ News/ Oncology

NICE backs use of MSD’s KEYTRUDA for triple-negative breast cancer

, , , , , , , 0 Comment

For the first time, patients in England with triple-negative breast cancer (TNBC) will be able to access immunotherapy

X
NICE backs use of MSD’s KEYTRUDA for triple-negative breast cancer
https://pharmaphorum.com/news/nice-backs-use-of-msds-keytruda-for-triple-negative-breast-cancer/

Login

CONTINUE TO SITE >
X
Close in 10 seconds